SAN CARLOS, Calif., June 6 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold the following events in June:
Pacific Growth Equities Life Sciences Growth Conference
June 12, 2006
4:00 p.m. PT
Lee Bendekgey, sr. vice president and general counsel http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NUVO&item_id=1315814
The Needham & Company, LLC Fifth Annual Biotechnology and Medical Technology Conference June 15, 2006 8:30 a.m. ET Gary Titus, CFO and CAO http://www.wsw.com/webcast/needham15/nuvo/ Nuvelo Research & Development Briefing for Investors & Analysts June 16, 2006 9:30 a.m. ET Nuvelo’s management and scientists will review the company’s clinical development of acute cardiovascular and cancer therapies. Speakers: Randall Higashida, M.D., of the University of California at San Francisco Medical Center Ted Love, M.D., chairman and CEO Michael Levy, M.D., sr. vice president research and development Steven Deitcher, M.D., vice president medical sciences Walter Funk, Ph.D., vice president research Jim Buchanan, Pharm.D., sr. director drug safety Webcast: www.nuvelo.com or visit the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in four Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex which recently completed Phase 2 clinical development in acute coronary syndromes; and a thrombin inhibiting aptamer for anticoagulation during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Estrin, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472, or nestrin@nuvelo.com
Web site: http://www.nuvelo.com//
